Advertisement

Advances in Diagnosis of Endometrial Hyperplasia

  • Jyoti Ramesh Chandran
Invited Mini Review
  • 25 Downloads

Abstract

Recent classification of endometrial hyperplasia (EM) has improved our understanding on endometrioid adenocarcinomas (ECs). There was a previous notion that an unopposed oestrogenic stimulation leads to hyperplastic proliferation and cytological atypia leading to development of EC. The recent concepts point towards Endometrial Intra Epithelial Neoplasia as mutationally activated and monoclonally imprinted condition (Sanderson et al. in Hum Reprod Update 23(2):232–254, 2017.  https://doi.org/10.1093/humupd/dmw042). Several diagnostic biomarkers are described which can prognosticate development to EC. A ‘Panel approach’ to these biomarkers will help to prognosticate the disease progression (2016).

Keywords

Endometrial intra epithelial neoplasia (EIN) Endometrial hyperplasia Biomarkers 

Notes

Compliance with Ethical Standards

Conflict of interest

The author declares that she has no conflict of interest.

References

  1. 1.
    Sanderson PA, Critchley HOD, et al. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23(2):232–54.  https://doi.org/10.1093/humupd/dmw042.PubMedGoogle Scholar
  2. 2.
    Wise MR, Jordan V, Lagas A, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. Am J Obstet Gynecol. 2016;214:689.e1–17.CrossRefGoogle Scholar
  3. 3.
    Baak JPA, Ørbo A, van Diest PJ, et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol. 2001;25:930–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Critchley HOD, Brenner RM, Henderson TA, et al. Saunders PTK. Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J Clin Endocrinol Metab. 2001;86:1370–8.PubMedGoogle Scholar
  5. 5.
    Gallos ID, Alazzam M, Clark T, et al. RCOG green-top guideline: management of endometrial hyperplasia. 2016. https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf.
  6. 6.
    Upson K, Allison KH, Reed SD, et al. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am J Obstet Gynecol. 2012;207:36.e1–8.CrossRefGoogle Scholar
  7. 7.
    Tong BJ, Tan J, Tajeda L, et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor- δ in human endometrial adenocarcinoma. Neoplasia. 2000;2:483–90.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Wallace AE, Gibson DA, Saunders PTK, et al. Inflammatory events in endometrial adenocarcinoma. J Endocrinol. 2010;206:141–57.CrossRefPubMedGoogle Scholar
  9. 9.
    Daikoku T, Hirota Y, Tranguch S, et al. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res. 2008;68:5619–27.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924–30.CrossRefPubMedGoogle Scholar
  11. 11.
    Soong R, Robbins PD, Dix BR, et al. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol. 1996;27:1050–5.CrossRefPubMedGoogle Scholar
  12. 12.
    Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Quick CM, Laury AR, Monte NM, et al. Utility of PAX2 as a marker for diagnosis of endometrial intraepithelial neoplasia. Am J Clin Pathol. 2012;138:678–84.CrossRefPubMedGoogle Scholar
  14. 14.
    Jones A, Teschendorff AE, Li Q, et al. Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med. 2013;10:e1001551.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24:4783–91.CrossRefPubMedGoogle Scholar
  16. 16.
    Scholten AN, Creutzberg CL, van den Broek LJCM, et al. Smit VTHBM. Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma. J Pathol. 2003;201:460–5.CrossRefPubMedGoogle Scholar
  17. 17.
    Kokawa K, Shikone T, Otani T, et al. Apoptosis and the expression of Bax and Bcl-2 in hyperplasia and adenocarcinoma of the uterine endometrium. Hum Reprod. 2001;16:2211–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Malpani A, Singer J, Wolverson MK, et al. Endometrial hyperplasia: value of endometrial thickness in ultrasonographic diagnosis and clinical significance. J Clin Ultrasound. 1990;18:173–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Bourne TH, Campbell S, Steer CV, et al. Detection of endometrial cancer by transvaginal ultrasonography with color flow imaging and blood flow analysis: a preliminary report. Gynecol Oncol. 1991;40:253–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Garuti G, Cellani F, et al. Accuracy of hysteroscopic diagnosis of endometrial hyperplasia: a retrospective study of 323 patients. J Minim Invasive Gynecol. 2005;12(3):247–53.CrossRefPubMedGoogle Scholar

Copyright information

© Federation of Obstetric & Gynecological Societies of India 2018

Authors and Affiliations

  1. 1.Obstetrics and Gynaecology, Institute of Maternal and Child HealthGovernment Medical College KozhikodeKozhikodeIndia

Personalised recommendations